[go: up one dir, main page]

 
 

Mitochondrial Dysfunction and Oxidative Stress

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 1687

Special Issue Editor


E-Mail Website
Guest Editor
Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal
Interests: diabetes; Alzheimer´s disease; mental disorders; mitochondria; oxidative stress; uncoupling proteins; brain metabolism
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Mitochondria, special double-membrane-bound intracellular organelles found in the cells of most eukaryotes, are universally regarded as the powerhouse of the cell. However, in addition to supplying energy, mitochondria fulfill several other roles that contribute to the regulation of the cell’s proper function, as is the case of reactive oxygen species (ROS) formation and neutralization. Having a recognized role as signaling molecules, ROS, when in excessive levels, elicit an imbalance in cellular redox status, leading to a condition of oxidative stress that can cause damage to organelles, including mitochondria itself, as well as tissues and organs in the body. resulting in a vast number of diseases. As many lines of evidence suggest, perturbations in mitochondria physiological function, energy metabolism regulation and oxidative status are critically linked with the pathophysiology of many neurodevelopmental, neuropsychiatric, and neurodegenerative disorders.

Considering the importance of the subject, this Special Issue intends to collect basic and preclinical studies that may cover all research aspects related to mitochondria homeostasis and deregulation, metabolic disturbances, as well as redox biology and its interplay with diverse brain pathologies that impact the human organism from birth to old age. Comprehensive and critical reviews within the topic are also welcome. 

Dr. Susana Cardoso
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mitochondria
  • oxidative stress
  • brain metabolism
  • neurodevelopmental diseases
  • neuropsychiatric diseases
  • neurodegenerative diseases
  • mitochondrial medicine
  • translational medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

30 pages, 1566 KiB  
Review
Mitochondrial Dysfunction in Neurodegenerative Diseases: Mechanisms and Corresponding Therapeutic Strategies
by Kai Meng, Haocheng Jia, Xiaoqing Hou, Ziming Zhu, Yuguang Lu, Yingying Feng, Jingwen Feng, Yong Xia, Rubin Tan, Fen Cui and Jinxiang Yuan
Biomedicines 2025, 13(2), 327; https://doi.org/10.3390/biomedicines13020327 - 31 Jan 2025
Viewed by 927
Abstract
Neurodegenerative disease (ND) refers to the progressive loss and morphological abnormalities of neurons in the central nervous system (CNS) or peripheral nervous system (PNS). Examples of neurodegenerative diseases include Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). Recent studies have [...] Read more.
Neurodegenerative disease (ND) refers to the progressive loss and morphological abnormalities of neurons in the central nervous system (CNS) or peripheral nervous system (PNS). Examples of neurodegenerative diseases include Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). Recent studies have shown that mitochondria play a broad role in cell signaling, immune response, and metabolic regulation. For example, mitochondrial dysfunction is closely associated with the onset and progression of a variety of diseases, including ND, cardiovascular diseases, diabetes, and cancer. The dysfunction of energy metabolism, imbalance of mitochondrial dynamics, or abnormal mitophagy can lead to the imbalance of mitochondrial homeostasis, which can induce pathological reactions such as oxidative stress, apoptosis, and inflammation, damage the nervous system, and participate in the occurrence and development of degenerative nervous system diseases such as AD, PD, and ALS. In this paper, the latest research progress of this subject is detailed. The mechanisms of oxidative stress, mitochondrial homeostasis, and mitophagy-mediated ND are reviewed from the perspectives of β-amyloid (Aβ) accumulation, dopamine neuron damage, and superoxide dismutase 1 (SOD1) mutation. Based on the mechanism research, new ideas and methods for the treatment and prevention of ND are proposed. Full article
(This article belongs to the Special Issue Mitochondrial Dysfunction and Oxidative Stress)
Show Figures

Figure 1

Figure 1
<p>Aβ-Induced mitochondrial dysfunction triggers neuronal degeneration in AD. (<b>a</b>) Aβ protein, which is an AD marker, acts on mitochondria and causes a variety of mitochondrial abnormalities by inhibiting complex III/IV, OGDC, and PDH activity, which in turn inhibits ATP synthesis and induces the onset of mitophagy. The release of Cyt-c from the mitochondria into the cytoplasm is an important factor in mitophagy. The most important aspect is that Aβ causes the rise in ROS, while a large level of ROS inhibits PP2A and activates GSK 3β, leading to Tau over-phosphorylation, causing neuronal fiber tangles. At the same time, ROS promotes APP expression, APP further promotes ROS and Aβ production, and APP and Aβ block APP and Aβ production. This leads to tau hyperphosphorylation, which causes neuronal fiber tangles. Meanwhile, ROS promotes APP expression, while APP further promotes ROS and Aβ generation, and APP and Aβ block protein transport in mitochondria, causing neuronal damage. (<b>b</b>) Treatment of rat pericytes with low doses of Aβ significantly upregulated the expression of PINK1/Parkin and inhibited the phosphorylation of Tau, which in turn promoted mitophagy; however, the accumulation of Aβ in the neurons of AD patients, which is usually observed in pathological states, has been shown to inhibit mitophagy, leading to a decrease in the production of ROS, which causes neuronal apoptosis. (<b>c</b>) In neurons of the cerebral cortex of AD patients, Aβ protein causes S-nitrosylation of DRP1, which increases GTPase activity and accelerates mitochondrial fission; at the same time, Aβ interacts with DRP1 and activates DRP1 and FIS1, which results in mitochondrial fission, and both pathways contribute to apoptotic neuronal death. (<b>d</b>) High levels of phosphorylated tau have been observed in patients with AD or in 3XTg mice. Their presence promoted the interaction of Aβ with DRP1 in AD mouse models and triggered neuronal apoptosis by increasing GTPase activity. Aβ: Amyloid-β; OGDC: oxoglutarate dehydrogenase complex; PDH: pyruvate dehydrogenase; ROS: Reactive oxygen species; PP2A: proteinphosphatase 2A; GSK 3β: glycogen synthase kinase-3; APP: amyloid precursor protein; DRP1: Dynamic-related protein 1; FIS1: Mitochondrial fission protein 1.</p>
Full article ">Figure 2
<p>Mechanisms of mitochondrial homeostasis affecting PD. (<b>a</b>) In patients with PD, the excessive accumulation of ROS in the CNS leads to an imbalance in glutamate metabolism, neuronal excitotoxicity, and the release of Cyt-c. This results in an imbalance in mitochondrial homeostasis, secretion of the toxic lipid particles APOE and APOJ by astrocytes, and apoptosis of dopaminergic neurons, ultimately inducing PD. (<b>b</b>) In PD model mice, the knockout of PINK1 in dopaminergic neurons leads to mitochondrial calcium accumulation, resulting in mitochondrial calcium overload, increased ROS production, the promotion of mitochondrial fission, and the mediation of neuronal apoptosis. In the brains of these mice, dopaminergic cells are exposed to oxidative stress, with translocated DRP1 binding to P53 on the OMM, exacerbating oxidative stress and inhibiting GTP and ATP synthesis. Alternatively, DRP1-dependent mitochondrial fission is indirectly promoted by miR-499 transcription, thus mediating neuronal apoptosis and PD. In the neurons of PD patients, α-syn co-localizes with cardiolipin and rapidly oligomerizes, inhibiting complex I synthesis, reducing mitochondrial membrane potential difference, promoting the opening of the mPTP, and generating mROS. This accelerates mitochondrial oxidative stress, inhibits mitophagy, and induces neuronal apoptosis. In PD model rats, dopaminergic neurons exposed to neurotoxins, such as 6-OHDA, rotenone, and MPP+, induce Bax translocation to the OMM, resulting in the opening of mPTP, gradual loss of mitochondrial membrane potential, excessive release of Cyt-c and AIF, activation of caspase-9, and formation of apoptosomes, resulting in cell apoptosis and inducing PD. (<b>c</b>) In the microglia of patients with PD, the LRRK2 G2019S mutation inhibits the removal of MIRO, causing mitochondrial oxidative stress, suppressing mitophagy, and leading to excessive cell activation. In the brain tissue of PD model mice exposed to copper, activated microglia secrete inflammatory products, upregulate NLRP3/caspase-1 axis proteins, downregulate Parkin and PINK1, promote ROS generation, and activate the NF-κB pathway. This inhibits mitophagy and activates microglia to synthesize and release pro-NGF, which binds to the sortilin receptor, upregulates JNK and c-Jun proteins, and activates the JNK-JUN signaling pathway. This sequence initiates neuronal apoptosis, induces dopaminergic neuronal apoptosis, and triggers PD. Cyt-c: cytochrome C; APOE: apolipoprotein E.; APOJ: apolipoprotein E; PINK1: PTEN-induced putative kinase 1. OMM: outer mitochondrial membrane. GTP: Guanosine triphosphate. ATP: Adenosine triphosphate. α-syn: alpha-Synuclein. mPTP: mitochondrial permeability transition pore. mROS: Mitochondrial reactive oxygen species. 6-OHDA: 6-hydroxydopamine. MPP+: 1-methyl-4-phenylpyridinium. AIF: Apoptosis-inducing factor. Caspase 9: Cysteine-requiring Aspartate Protease 9. MIRO: mitochondrial Rho. NLRP3: Nucleotide-binding oligomerization domain receptor 3. Caspase1: Cysteine-requiring Aspartate Protease 1. ProNGF: pro-nerve growth factor. JNK: c-Jun N-Terminal Kinase.</p>
Full article ">Figure 3
<p>Mechanisms of mitochondrial dysfunction and neuronal apoptosis in ALS. (<b>a</b>) DRP1 is overexpressed in the cytoplasm of ganglion cells of ALS model rats, where it binds to APAF1, recruiting and activating the precursor of caspase-9. This upregulates the expression of the apoptotic execution protein caspase-3, promotes mitochondrial fission, and induces neuronal apoptosis. DRP1, by translocating and binding to the mitochondrial membrane, opens the mPTP, releasing ROS and Cyt-c, leading to mitochondrial oxidative stress, mitochondrial fission dysfunction, and neuronal apoptosis. (<b>b</b>) In patients with ALS, C9orf72 expansion upregulates TDP-43, promoting the transcription of ND3/6 mRNA, which inhibits mitochondrial complex I. The activation of mPTP promotes mtDNA release, activates the cGAS-STING signaling pathway, and induces an inflammatory response. Following treatment with CCCP, the overexpression of TDP-43 downregulated caspase-3 and promoted autophagosome formation, leading to sustained mitochondrial fission, disruption of mitochondrial homeostasis, and the induction of neuronal apoptosis. In patients with ALS, OPTN mutations cause failure to bind to LC3B in damaged mitochondria and exhibit aberrant localization. The clearance of damaged mitochondria by OPTN is inhibited, leading to abnormal mitophagy and ALS induction. APAF 1: apoptotic protease-activating factor 1. Caspase 3: Cysteine-requiring Aspartate Protease 3. C9orf72: chromosome 9 open reading frame 72. TDP-43: TAR DNA-binding protein, 43 kDa. mtDNA: Mitochondrial DNA. cGAS-STING: Cyclic GMP-AMP synthase stimulator of interferon genes. CCCP: carbonyl cyanide, m-chlorophenyl hydrazone. OPTN: optineurin. LC3B: microtubule-associated protein light chain 3 beta.</p>
Full article ">
Back to TopTop